Cervix Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CRV040 MIFTS: 53	Cervix Carcinoma Categories: Cancer diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Cervix Carcinoma

MalaCards integrated aliases for Cervix Carcinoma:

Name: Cervix Carcinoma ¹² ¹⁵ ⁷⁴

Carcinoma of Cervix ¹² ³⁰ ⁶

Carcinoma of the Cervix Uteri ¹²

Carcinoma Cervix Uteri ¹²

Cancer of Cervix ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:2893

NCIt ⁵¹ C9039

SNOMED-CT ⁶⁹ 93752005

UMLS ⁷⁴ C0302592

Sources

Summaries for Cervix Carcinoma

Disease Ontology : ¹² A cervical cancer that is located in the cervix uteri or located in the cervical area and that has material basis in abnormally proliferating cells derives from epithelial cells.

MalaCards based summary : Cervix Carcinoma, also known as carcinoma of cervix, is related to cervix small cell carcinoma and suppressor of tumorigenicity 3. An important gene associated with Cervix Carcinoma is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are MAPK signaling pathway and MicroRNAs in cancer. The drugs Aluminum hydroxide and Bethanechol have been mentioned in the context of this disorder. Affiliated tissues include cervix, testes and lymph node, and related phenotypes are Decreased viability in esophageal squamous lineage and homeostasis/metabolism

Sources

Related Diseases for Cervix Carcinoma

Diseases related to Cervix Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 126)

#	Related Disease	Score	Top Affiliating Genes
1	cervix small cell carcinoma	31.7	CDKN2A MAPK8IP1 MAPK8IP2 TP53
2	suppressor of tumorigenicity 3	31.6	CDKN2A FHIT TP53
3	endocervical carcinoma	31.3	CDKN2A MAPK8IP1
4	cervical cancer	31.1	CDKN2A FGFR3 FHIT HOXA11-AS STAT3 TP53
5	keratinizing squamous cell carcinoma	29.7	CDKN2A TP53
6	anal squamous cell carcinoma	29.5	CDKN2A TP53
7	transitional cell carcinoma	29.4	CDKN2A FGFR3 TP53
8	papilloma	29.3	CDKN2A FGFR3 TP53
9	high-grade neuroendocrine carcinoma of the cervix uteri	12.5
10	glassy cell carcinoma of the cervix uteri	12.4
11	adenoid basal carcinoma of the cervix uteri	12.4
12	papillary carcinoma of the cervix uteri	12.4
13	cervix uteri carcinoma in situ	11.7
14	cervical clear cell adenocarcinoma	11.4
15	cervical endometrioid adenocarcinoma	11.4
16	primitive neuroectodermal tumor of the cervix uteri	11.2
17	cervical adenosquamous carcinoma	11.1
18	cervical squamous cell carcinoma	11.1
19	exocervical carcinoma	11.1
20	cervical adenocarcinoma	11.1
21	cervical adenoid cystic carcinoma	11.1
22	cervical adenoid basal carcinoma	11.1
23	cervical large cell neuroendocrine carcinoma	11.1
24	non-invasive bladder papillary urothelial neoplasm	10.3	FGFR3 TP53
25	bladder papillary transitional cell neoplasm	10.3	FGFR3 TP53
26	urinary tract papillary transitional cell benign neoplasm	10.3	FGFR3 TP53
27	in situ carcinoma	10.3
28	aging	10.2	FOXO3 STAT3 TP53
29	ophthalmia neonatorum	10.2	MAPK8IP1 STYK1
30	bladder squamous cell carcinoma	10.1	CDKN2A TP53
31	spitz nevus	10.1	CDKN2A TP53
32	adenocarcinoma	10.1
33	skin carcinoma in situ	10.1	CDKN2A STAT3
34	xp22.3 microdeletion syndrome	10.1
35	basal cell carcinoma 1	10.1
36	basal cell carcinoma	10.1
37	verrucous carcinoma	10.1
38	cystic basal cell carcinoma	10.1
39	bladder carcinoma in situ	10.0	CDKN2A TP53
40	vulva squamous cell carcinoma	10.0	CDKN2A TP53
41	bone squamous cell carcinoma	10.0	CDKN2A STAT3
42	scrotal carcinoma	10.0	CDKN2A TP53
43	adenoid cystic carcinoma	10.0
44	adenosquamous carcinoma	10.0
45	megaesophagus	10.0	CDKN2A FHIT TP53
46	barrett's adenocarcinoma	10.0	CDKN2A FHIT TP53
47	gastric adenosquamous carcinoma	10.0	CDKN2A STAT3 TP53
48	supratentorial cancer	10.0	CDKN2A STAT3 TP53
49	cerebrum cancer	10.0	CDKN2A STAT3 TP53
50	thyroid lymphoma	10.0	CDKN2A TP53

Graphical network of the top 20 diseases related to Cervix Carcinoma:

Sources

Symptoms & Phenotypes for Cervix Carcinoma

GenomeRNAi Phenotypes related to Cervix Carcinoma according to GeneCards Suite gene sharing:

²⁷

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability in esophageal squamous lineage	GR00235-A	9.28	CDKN2A CDKN3 DUSP3 FGFR3 FOXO3 MAPK8IP1

MGI Mouse Phenotypes related to Cervix Carcinoma:

⁴⁷

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.07	ABCC1 CDKN2A DUSP3 FGFR3 FHIT FOXM1
2	digestive/alimentary	MP:0005381	9.97	CDKN2A FGFR3 FHIT FOXM1 FOXO3 SLC16A1
3	mortality/aging	MP:0010768	9.93	ABCC1 CDKN2A FGFR3 FHIT FOXM1 FOXO3
4	endocrine/exocrine gland	MP:0005379	9.92	CDKN2A FOXM1 FOXO3 MAPK8IP1 MAPK8IP2 NBN
5	neoplasm	MP:0002006	9.56	CDKN2A FGFR3 FHIT FOXM1 FOXO3 NBN
6	reproductive system	MP:0005389	9.23	CDKN2A FGFR3 FOXO3 MAPK8IP1 MAPK8IP2 NBN

Sources

Drugs & Therapeutics for Cervix Carcinoma

Drugs for Cervix Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 498)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Aluminum hydroxide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

21645-51-2

Bethanechol

Approved

Phase 4

674-38-4

2370

Peppermint

Approved

Phase 4

Cisplatin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

15663-27-1

441203 84093 2767

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4,Phase 3,Not Applicable

437-38-7

3345

Ritonavir

Approved, Investigational

Phase 4,Phase 3,Phase 2

155213-67-5

392622

Meperidine

Approved

Phase 4

57-42-1

4058

Diazepam

Approved, Illicit, Investigational, Vet_approved

Phase 4

439-14-5

3016

Polihexanide

Approved, Investigational

Phase 4

28757-47-3

Dopamine

Approved

Phase 4,Phase 2

62-31-7, 51-61-6

681

Bupropion

Approved

Phase 4,Phase 2

34841-39-9, 34911-55-2

444

Nicotine

Approved

Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1

54-11-5

942 89594

Nevirapine

Approved

Phase 4

129618-40-2

4463

Emtricitabine

Approved, Investigational

Phase 4

143491-57-0

60877

Ferrous fumarate

Approved

Phase 4

141-01-5

Iron

Approved, Experimental

Phase 4

7439-89-6, 15438-31-0

23925 27284

Vitamin C

Approved, Nutraceutical

Phase 4,Phase 2

50-81-7

5785 54670067

Tenofovir

Experimental, Investigational

Phase 4

147127-20-6

464205

Vaccines

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1

Immunologic Factors

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Monophosphoryl lipid A

Phase 4

Cholinergic Agents

Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1

Autonomic Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Neurotransmitter Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Muscarinic Agonists

Phase 4

Liver Extracts

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antibodies

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Immunoglobulins

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Epoetin alfa

Phase 4,Phase 3

113427-24-0

Hematinics

Phase 4,Phase 3,Phase 2,Phase 1

Narcotics

Phase 4,Phase 3,Not Applicable,Early Phase 1

Anesthetics

Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

Anesthetics, Intravenous

Phase 4,Phase 3,Not Applicable

Analgesics, Opioid

Phase 4,Phase 3,Not Applicable

Central Nervous System Depressants

Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

Analgesics

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Adjuvants, Anesthesia

Phase 4,Phase 3,Not Applicable

Anesthetics, General

Phase 4,Phase 3,Not Applicable

Pharmaceutical Solutions

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Anti-Infective Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Cytochrome P-450 Enzyme Inhibitors

Phase 4,Phase 3,Phase 2

Psychotropic Drugs

Phase 4,Phase 3,Phase 2

Nucleic Acid Synthesis Inhibitors

Phase 4,Phase 3,Phase 2,Phase 1

Anti-Retroviral Agents

Phase 4,Phase 3,Phase 2,Phase 1

Anti-HIV Agents

Phase 4,Phase 3,Phase 2,Phase 1

HIV Protease Inhibitors

Phase 4,Phase 3,Phase 2,Phase 1

Cytochrome P-450 CYP3A Inhibitors

Phase 4,Phase 3,Phase 2

Antiviral Agents

Phase 4,Phase 3,Phase 2,Phase 1

protease inhibitors

Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 1374)

#	Name	Status	NCT ID	Phase	Drugs
1	FASTER-Tlalpan Study	Unknown status	NCT03105856	Phase 4
2	Comparing Health Services Interventions for the Prevention of HPV-related Cancer	Unknown status	NCT02837926	Phase 4
3	Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China	Unknown status	NCT01021904	Phase 4
4	Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA	Unknown status	NCT02910596	Phase 4	bethanechol chloride
5	Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?	Unknown status	NCT01101750	Phase 4
6	Can Alternative Treatment Have an Impact on Cervical Dysplasia?	Unknown status	NCT00842738	Phase 4
7	Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females	Unknown status	NCT01031069	Phase 4
8	Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients	Unknown status	NCT02624349	Phase 4	Quadravalent human papillomavirus vaccine
9	Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies	Unknown status	NCT01835119	Phase 4	gum
10	Epoetin Beta in Treating Anemia in Patients With Cervical Cancer	Completed	NCT00046969	Phase 4	cisplatin
11	Effect of HPV Vaccination on Women Aged 25 Years	Completed	NCT02296255	Phase 4
12	Patient Navigation in the Safety Net:CONNECTeDD	Completed	NCT00613275	Phase 4
13	V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)	Completed	NCT01544478	Phase 4
14	Application of Tachosil During Lymphadenectomy	Completed	NCT03752606	Phase 4
15	Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls	Completed	NCT01173900	Phase 4
16	Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects	Completed	NCT00947115	Phase 4
17	Alternate Dosing Schedules Study for HPV Vaccine	Completed	NCT00862810	Phase 4
18	Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls	Completed	NCT00956553	Phase 4
19	Comparison of Meperidine and Fentanyl on Pain Scale and QOL in Brachytherapy	Completed	NCT02684942	Phase 4	Meperidine;Fentanyl
20	Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents	Completed	NCT00534638	Phase 4
21	Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease	Completed	NCT00815282	Phase 4
22	Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection	Completed	NCT01571141	Phase 4
23	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking	Completed	NCT00666978	Phase 4	bupropion hydrochloride
24	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking	Completed	NCT00365508	Phase 4	nicotine lozenge;nicotine patch
25	The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.	Completed	NCT03384511	Phase 4	Apatinib
26	Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)	Completed	NCT00552240	Phase 4	tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
27	Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.	Recruiting	NCT03423082	Phase 4	18F fluciclovine
28	Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines	Recruiting	NCT03180034	Phase 4
29	Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study	Recruiting	NCT01824537	Phase 4
30	Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.	Recruiting	NCT03349463	Phase 4	Fluciclovine F18
31	Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study	Recruiting	NCT03629886	Phase 4
32	CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening （CITRUS Study）	Active, not recruiting	NCT01895517	Phase 4
33	The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP)	Active, not recruiting	NCT02629510	Phase 4	Tachosil
34	Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India	Active, not recruiting	NCT00923702	Phase 4
35	Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.	Active, not recruiting	NCT01953107	Phase 4
36	The KEN SHE Study on HPV-vaccine Efficacy	Enrolling by invitation	NCT03675256	Phase 4
37	To Evaluate the Efficacy and Safety of PEG-rhG-CSF（Jinyouli®） in Reducing Neutropenia in Patients With Cervical Cancer	Not yet recruiting	NCT03206684	Phase 4	PEG-rhG-CSF;rhG-CSF
38	Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities	Terminated	NCT00629993	Phase 4
39	A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.	Terminated	NCT00730847	Phase 4
40	Cisplatin Based Chemoradiation v.s Radiotherapy for Cervical Cancer and With Clinically Defined Good Prognosis	Unknown status	NCT00846508	Phase 3	Cisplatin
41	Randomized Trial Between Weekly and 5 Day 3 Weekly Cisplatin for Cervical Cancer	Unknown status	NCT00548821	Phase 3	Cisplatin
42	Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer	Unknown status	NCT02446652	Phase 3	Hydralazine/Magnesium;Placebo;Carboplatin;Paclitaxel
43	Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer	Unknown status	NCT01554397	Phase 2, Phase 3	Cisplatin
44	Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical Cancer	Unknown status	NCT00842660	Phase 3	Gemzar (gemcitabine)
45	Adjuvant Chemotherapy for Locally Advanced Cervical Cancer	Unknown status	NCT02036164	Phase 3	Cisplatin;Paclitaxel;Carboplatin
46	Postoperative Chemoradiation v.s Radiotherapy for Lymph Node Negative Cervical Cancer Patients	Unknown status	NCT01756170	Phase 3	paclitaxel;cisplatin
47	Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients	Unknown status	NCT01755845	Phase 3	paclitaxel;cisplatin
48	Evaluation of Postoperative Radiotherapy and Concurrent Chemotherapy Effectiveness in Cervical Cancer	Unknown status	NCT01999933	Phase 2, Phase 3	cisplatin（DDP） weekly;docetaxel plus cisplatin;docetaxel plus cisplatin
49	Usefulness of FDG-PET for Advanced Cervical Cancer	Unknown status	NCT00146458	Phase 3
50	Comparing Study Between Concurrent Chemoradiation and New Combination Treatment in Cervical Cancer Patients	Unknown status	NCT01000415	Phase 3

Search NIH Clinical Center for Cervix Carcinoma

Sources

Genetic Tests for Cervix Carcinoma

Genetic tests related to Cervix Carcinoma:

#	Genetic test	Affiliating Genes
1	Carcinoma of Cervix ³⁰	FGFR3

Sources

Anatomical Context for Cervix Carcinoma

MalaCards organs/tissues related to Cervix Carcinoma:

⁴²

Cervix, Testes, Lymph Node, Breast, T Cells, Lung, Uterus

The Foundational Model of Anatomy Ontology organs/tissues related to Cervix Carcinoma:

²⁰

The Cervix Uteri Or

Sources

Publications for Cervix Carcinoma

Articles related to Cervix Carcinoma:

(show top 50) (show all 405)

#	Title	Authors	Year
1	Treatment of cervix carcinoma FIGO IIIb with Photofrin II as a radiosensitizer: a case report. ( 30892313 )	Schaffer P...Schaffer M	2019
2	Small cell carcinoma of cervix: A population-based study evaluating standardized provincial treatment protocols. ( 30723760 )	Roy S...Bahl G	2019
3	Increasing aggressiveness of patient-derived xenograft models of cervix carcinoma during serial transplantation. ( 29765518 )	Wegner C.S....Rofstad E.K.	2018
4	Tanshinone IIA inhibits cervix carcinoma stem cells migration and invasion via inhibiting YAP transcriptional activity. ( 29909343 )	Qin J....Wang Q.	2018
5	Squamous cell carcinoma of cervix origin with rare metastasis to the colon. ( 30264019 )	Lelchuk A...Bain K	2018
6	Comparative Evaluation of a 6MV Flattened Beam and a Flattening Filter Free Beam for Carcinoma of Cervix – IMRT Planning Study ( 29580032 )	Tamilarasu S...Dewan A	2018
7	Paclitaxel dimers assembling nanomedicines for treatment of cervix carcinoma. ( 28359677 )	Pei Q....Jing X.	2017
8	Dosimetric influence of filtered and flattening filter free photon beam on rapid arc (RA) radiotherapy planning in case of cervix carcinoma. ( 27790073 )	Kumar L....Pal M.	2017
9	The induction of oxidative stress in cervix carcinoma cells by levoglucosenone derived 4-S-salicyl derivative and (1-4)-S-thio-disaccharides. Part 4. ( 28185719 )	Sarnik J....Poplawski T.	2017
10	DCE-MRI of patient-derived xenograft models of uterine cervix carcinoma: associations with parameters of the tumor microenvironment. ( 29100521 )	Hauge A....Rofstad E.K.	2017
11	Extra-peritoneal laparoscopic para-aortic lymphadenectomy for staging of uterine cervix carcinoma. ( 28153518 )	Neveu M.E....Gouy S.	2017
12	Lymphoepithelioma-like carcinoma of cervix: Cytological Features on Conventional Cervical Smear. ( 28211234 )	Rathore R....Singh B.	2017
13	Squamous Cell Carcinoma of Cervix with Isolated Metastasis to Ethmoidal Sinus: A Rare Occurrence. ( 28658774 )	Pradhan P...Kumar A	2017
14	Association of Neo Angiogenesis by CD34 Expression and Clinicopathologic Features in Squamous Cell Carcinoma of Cervix. ( 28724267 )	Sarmadi S...Jahanzad E	2017
15	Dosimetric study for cervix carcinoma treatment using intensity modulated radiation therapy (IMRT) compensation based on 3D intracavitary brachytherapy technique. ( 27504132 )	Yin G....Tam K.Y.	2016
16	SU-F-T-62: Three-Dimensional Dosimetric Gamma Analysis for Impacts of Tissue Inhomogeneity Using Monte Carlo Simulation in Intracavitary Brachytheray for Cervix Carcinoma. ( 28048200 )	Nguyen T.T....Yoshiura T.	2016
17	RGDS- and TAT-Conjugated Upconversion of NaYF4:Yb(3+)/Er(3+)&amp;SiO2 Nanoparticles: In Vitro Human Epithelioid Cervix Carcinoma Cellular Uptake, Imaging, and Targeting. ( 27428386 )	Kostiv U....HorA!k D.	2016
18	Image-Guided High-Dose Rate Brachytherapy in Cervix Carcinoma Using Balloon Catheter and Belt Immobilization System. ( 26868850 )	Fan Q....Lu B.	2016
19	Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study. ( 27368915 )	Naik A....Bhandari V.	2016
20	STAT3:FOXM1 and MCT1 drive uterine cervix carcinoma fitness to a lactate-rich microenvironment. ( 26563366 )	Silva L.S....Serpa J.	2016
21	Modulation of RhoA GTPase Activity Sensitizes Human Cervix Carcinoma Cells to I^-Radiation by Attenuating DNA Repair Pathways. ( 26649141 )	Osaki J.H....Forti F.L.	2016
22	Pulsed-dose-rate vs. high-dose-rate intracavitary radiotherapy for locally advanced carcinoma of cervix: A prospective randomized study. ( 26996595 )	Kumar P...Julka PK	2016
23	Concurrent Cisplatin-Based Chemoradiation in Squamous Cell Carcinoma of Cervix. ( 27097702 )	Hashmi H...Ahmed A	2016
24	Clinicopathological Significance of Vimentin and Cytokeratin Protein in the Genesis of Squamous Cell Carcinoma of Cervix. ( 27190522 )	Husain NE...Rahmani AH	2016
25	Systematic gene microarray analysis of the lncRNA expression profiles in human uterine cervix carcinoma. ( 26054679 )	Chen J....Shen Y.	2015
26	Basaloid squamous cell carcinoma of cervix showing neuroendocrine differentiation. ( 26148627 )	Majhi U....Srinivasan V.	2015
27	Metastatic lobular carcinoma of breast mimics primary cervix carcinoma: two case reports and a review of the literature. ( 26435744 )	Lokadasan R....Nair S.P.	2015
28	Evaluation of outcome and prognostic factors in 739 patients with uterine cervix carcinoma: a single institution experience. ( 26034391 )	Teke F....A9nsal M.	2015
29	The dosimetric impact of different photon beam energy on RapidArc radiotherapy planning for cervix carcinoma. ( 26865756 )	Kumar L....Pal M.	2015
30	The association of GSTM1 and GSTT1 polymorphisms with squamous cell carcinoma of cervix in Pakistan. ( 25663492 )	Hasan S....Azhar A.	2015
31	Adenoid cystic carcinoma of cervix: two cases report and review of the literature. ( 26090035 )	Benhayoune K...Harmouch T	2015
32	A Rare Case of Metastasis of Small Cell Carcinoma of Cervix to Breast. ( 29147420 )	Yadav D...Chisti MM	2015
33	Characterization of Toll-like receptor transcriptome in squamous cell carcinoma of cervix: A case-control study. ( 26024767 )	Aggarwal R...Minz R	2015
34	Clear cell carcinoma of cervix in a postmenopausal woman: A case report. ( 26167060 )	Pal S...Bose K	2015
35	An Audit of 204 Histopathology Reports Over Three Years of Carcinoma of Cervix: Experience from a Tertiary Referral Centre. ( 26320429 )	Pradhan AP...Deodhar K	2015
36	Evaluation of Survival and Treatment Toxicity With High-Dose-Rate Brachytherapy With Cobalt 60 in Carcinoma of Cervix. ( 26478798 )	Rakhsha A...Hoseini SM	2015
37	Invasive squamous cell carcinoma of cervix showing horizontal endometrial spread with extension and involvement of the myometrium: A case report. ( 26960456 )	Chandrashekhara SH...Dadhwal V	2015
38	Small cell neuroendocrine carcinoma of cervix and leiomyoma between the vagina and rectum. ( 25058833 )	Sheth S....Arneja S.	2014
39	Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy. ( 24666257 )	Chen J.L....Kuo S.H.	2014
40	Cervix carcinoma and incidental finding of medullary thyroid carcinoma by 18F-FDG PET/CT--clinical case. ( 25088110 )	Chaushev B....Nenkov R.	2014
41	Synthetic racemates of abyssinone I and II induces apoptosis through mitochondrial pathway in human cervix carcinoma cells. ( 25019692 )	Samaga K.K....Diwakar L.	2014
42	Peptidyl-prolyl isomerase Pin1-mediated abrogation of APC-I^-catenin interaction in squamous cell carcinoma of cervix. ( 24715170 )	Jawanjal P....Rath G.	2014
43	Adenoid cystic carcinoma of cervix in younger women: report of two new cases. ( 25722772 )	Sinaa M...Albouzidi A	2014
44	Human papilloma virus 16/18 genotypes in patients with squamous cell carcinoma of cervix in northeast Iran. ( 25538369 )	Ayatollahi H...Sheikhi M	2014
45	Abdominal scar recurrence of squamous cell carcinoma of cervix following simple hysterectomy. ( 25404838 )	Arora RS...Patel J	2014
46	Pre-treatment haemoglobin and peripheral blood lymphocyte count as independent predictors of outcome in carcinoma of cervix. ( 24439272 )	Hoskin PJ...Chong IY	2014
47	Significance of the plasma lipid profile in cases of carcinoma of cervix: a tertiary hospital based study. ( 24870793 )	Raju K...Kai LJ	2014
48	Concurrent chemoradiation for carcinoma of cervix: what lies beyond? ( 25022369 )	Gandhi AK...Rath GK	2014
49	Concurrent chemo-irradiation with weekly cisplatin and paclitaxel in the treatment of locally advanced squamous cell carcinoma of cervix: a phase II study. ( 25022387 )	Varghese SS...Viswanathan PN	2014
50	Continuous low-dose oral chemotherapy in recurrent and persistent carcinoma of cervix following chemoradiation: a comparative study between prolonged oral cyclophosphamide and oral Etoposide. ( 25191008 )	Baruah U...Shrivastava S	2014

Sources

Genes for Cervix Carcinoma

Genes related to Cervix Carcinoma (1 elite genes):

(show all 18)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	FGFR3	Fibroblast Growth Factor Receptor 3	Protein Coding	500	Pathogenic ⁶ Genetic Tests ³⁰	8589699 10471491 15772091
2	HOXA11-AS	HOXA11 Antisense RNA	RNA Gene	153.22	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵	26054679
3	TP53	Tumor Protein P53	Protein Coding	22.33	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	FHIT	Fragile Histidine Triad	Protein Coding	20.63	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	19.87	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	CDKN3	Cyclin Dependent Kinase Inhibitor 3	Protein Coding	19.49	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	DUSP3	Dual Specificity Phosphatase 3	Protein Coding	19.39	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	MAPK8IP1	Mitogen-Activated Protein Kinase 8 Interacting Protein 1	Protein Coding	17.46	DISEASES inferred ¹⁵
9	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	16.73	DISEASES inferred ¹⁵
10	FOXO3	Forkhead Box O3	Protein Coding	16.37	GeneCards inferred via : Publications (show sections)
11	ABCC1	ATP Binding Cassette Subfamily C Member 1	Protein Coding	16.37	GeneCards inferred via : Publications (show sections)
12	ARHGAP8	Rho GTPase Activating Protein 8	Protein Coding	16.37	GeneCards inferred via : Publications (show sections)
13	SLC16A1	Solute Carrier Family 16 Member 1	Protein Coding	16.37	GeneCards inferred via : Publications (show sections)
14	FOXM1	Forkhead Box M1	Protein Coding	16.37	GeneCards inferred via : Publications (show sections)
15	NBN	Nibrin	Protein Coding	16.37	GeneCards inferred via : Publications (show sections)
16	CDC27	Cell Division Cycle 27	Protein Coding	9.64	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	STYK1	Serine/Threonine/Tyrosine Kinase 1	Protein Coding	6.95	GeneCards inferred via : Expressions (show sections)
18	MAPK8IP2	Mitogen-Activated Protein Kinase 8 Interacting Protein 2	Protein Coding	6.84	DISEASES inferred ¹⁵

Sources

Variations for Cervix Carcinoma

ClinVar genetic disease variations for Cervix Carcinoma:

⁶

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	TP53	NM_000546.5(TP53): c.747G> T (p.Arg249Ser)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs28934571	GRCh37	Chromosome 17, 7577534: 7577534
2	TP53	NM_000546.5(TP53): c.747G> T (p.Arg249Ser)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs28934571	GRCh38	Chromosome 17, 7674216: 7674216
3	FGFR3	NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys)	single nucleotide variant	Pathogenic	rs121913483	GRCh37	Chromosome 4, 1803568: 1803568
4	FGFR3	NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys)	single nucleotide variant	Pathogenic	rs121913483	GRCh38	Chromosome 4, 1801841: 1801841

Sources

Expression for Cervix Carcinoma

Search GEO for disease gene expression data for Cervix Carcinoma.

Sources

Pathways for Cervix Carcinoma

Pathways related to Cervix Carcinoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	MAPK signaling pathway ¹ ³⁸	12.39	DUSP3 FGFR3 MAPK8IP1 MAPK8IP2 TP53
2	MicroRNAs in cancer ³⁸	12.13	ABCC1 CDKN2A FGFR3 STAT3 TP53
3	Glioma ³⁸ Show member pathways Endocrine resistance ³⁸ Melanoma ³⁸ Non-small cell lung cancer ³⁸ Signaling Pathways in Glioblastoma ¹	12.03	CDKN2A FGFR3 FHIT FOXO3 STAT3 TP53
4	DNA Damage ⁴	12.02	CDC27 CDKN2A FOXM1 NBN TP53
5	DNA Damage Response (only ATM dependent) ¹	11.67	CDKN2A FOXO3 TP53
6	Interleukin-4 and 13 signaling ⁶⁷	11.64	FOXO3 STAT3 TP53
7	Bladder cancer ³⁸ ¹	11.41	CDKN2A FGFR3 TP53
8	Cellular senescence (KEGG) ³⁸	11.23	CDKN2A FOXM1 FOXO3 NBN TP53

Sources

GO Terms for Cervix Carcinoma

Biological processes related to Cervix Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	apoptotic process	GO:0006915	9.88	CDKN2A FGFR3 FHIT FOXO3 TP53
2	cell cycle	GO:0007049	9.8	CDKN2A CDKN3 FOXM1 NBN TP53
3	positive regulation of transcription, DNA-templated	GO:0045893	9.77	CDKN2A FOXM1 FOXO3 STAT3 TP53
4	glucose homeostasis	GO:0042593	9.61	FOXO3 SLC16A1 STAT3
5	regulation of JNK cascade	GO:0046328	9.46	MAPK8IP1 MAPK8IP2
6	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	GO:0006978	9.32	FOXM1 TP53
7	replicative senescence	GO:0090399	9.26	CDKN2A TP53
8	cell cycle arrest	GO:0007050	9.26	CDKN2A CDKN3 NBN TP53
9	regulation of mitochondrial membrane permeability	GO:0046902	9.16	STAT3 TP53
10	DNA damage response, signal transduction by p53 class mediator	GO:0030330	8.8	FOXO3 NBN TP53

Molecular functions related to Cervix Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein phosphatase binding	GO:0019903	9.43	CDC27 STAT3 TP53
2	transcription factor binding	GO:0008134	9.35	CDKN2A FOXO3 NBN STAT3 TP53
3	protein kinase binding	GO:0019901	9.23	CDKN2A DUSP3 FOXM1 FOXO3 MAPK8IP1 MAPK8IP2
4	MAP-kinase scaffold activity	GO:0005078	9.16	MAPK8IP1 MAPK8IP2

Sources

Sources for Cervix Carcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia